Nektar Therapeutics (NKTR) FinancialsNKTRNektar Therapeutics

Evaluating the bottom line, Nektar Therapeutics maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -412.23%, while the net margin is -400.97%. These profitability ratios, combined with a Return on Equity (ROE) of -35.75%, provide a clear picture of how effectively NKTR converts its operational activities into shareholder value.

In the context of the broader market, NKTR competes directly with industry leaders such as OMER and PCRX. With a market capitalization of $1.41B, it holds a significant position in the sector. When comparing efficiency, NKTR's gross margin of 100.00% stands against OMER's 97.20% and PCRX's 69.60%. Such benchmarking helps identify whether Nektar Therapeutics is trading at a premium or discount relative to its financial performance.

Nektar's financial performance shows a troubling trend with net income losses, including a reported loss of $44,904,000 in Q1 2026 and $40,622,000 in Q2 2026. The gross margin is high at 100%, but revenue has been inconsistent, with total revenue for Q2 2026 at $10,131,000, down from $29,175,000 in Q4 2024.